Pulmonary Large Cell Neuroendocrine Carcinoma

doi:10.3389/pore.2022.1610730

	Pulmonary Large Cell Neuroendocrine Carcinoma
	Yang, Lan 1,2,3,4; Fan, Ying 1,2,3,4; Lu, Hongyang 1,2,3,4
刊名	PATHOLOGY & ONCOLOGY RESEARCH
	2022-10-11
卷号	28
关键词	treatment diagnosis LCNEC imaging examination pathologic features prognosis
ISSN号	1219-4956
DOI	10.3389/pore.2022.1610730
通讯作者	Lu, Hongyang(luhy@zjcc.org.cn)
英文摘要	Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare subtype of malignant pulmonary tumor. The incidence rate of LCNEC was reported to be 0.3%-3% in lung cancers. Although LCNEC is classified as non-small cell lung cancer (NSCLC), it is more aggressive and malignant than other NSCLC, and its biological behavior is similar to that of small cell lung cancer (SCLC). Most of the LCNEC patients are elderly smoking male and the clinical manifestations are not specific. The imaging manifestations of the tumors are often located in the periphery and the upper lobes, and the enlargement of mediastinal or hilar lymph nodes is common. The diagnosis is mainly based on pathology by the histological features and immunohistochemistry (IHC). Specific neuroendocrine markers such as chromogranin A (CgA), synaptophysin (Syn) and CD56 are usually diffusely positive in LCNEC, and found that insulinoma-associated protein (INSM1) and high rate of Ki-67 are helpful for diagnosis. More differential diagnoses also increase the difficulty of correctly diagnosing LCNEC. The rise of LCNEC molecular typing in recent years may be helpful for diagnosis and subsequent treatment. This review focuses on the epidemiological features, imaging studies, pathology, diagnosis, treatment, and prognosis of LCNEC.
资助项目	Zhejiang Provincial Natural Science Foundation of China ; Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China ; Beijing Science and Technology Innovation Medical Development Foundation ; [LY20H290003] ; [LHDMY22H160003] ; [KC2021-JX-0186-58]
WOS关键词	HEALTH-ORGANIZATION CLASSIFICATION ; LUNG-CARCINOMA ; ADJUVANT CHEMOTHERAPY ; SURGICAL-MANAGEMENT ; PROTEIN-1 INSM1 ; TUMORS ; CANCER ; IRINOTECAN ; DIAGNOSIS ; EFFICACY
WOS研究方向	Oncology ; Pathology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000874567500001
资助机构	Zhejiang Provincial Natural Science Foundation of China ; Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China ; Beijing Science and Technology Innovation Medical Development Foundation
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129891]
专题	中国科学院合肥物质科学研究院
通讯作者	Lu, Hongyang
作者单位	1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Zhejiang Key Lab Diag & Treatment Technol Thorac O, Hangzhou, Peoples R China 4.Wenzhou Med Univ, Clin Med Coll 2, Wenzhou, Peoples R China
推荐引用方式 GB/T 7714	Yang, Lan,Fan, Ying,Lu, Hongyang. Pulmonary Large Cell Neuroendocrine Carcinoma[J]. PATHOLOGY & ONCOLOGY RESEARCH,2022,28.
APA	Yang, Lan,Fan, Ying,&Lu, Hongyang.(2022).Pulmonary Large Cell Neuroendocrine Carcinoma.PATHOLOGY & ONCOLOGY RESEARCH,28.
MLA	Yang, Lan,et al."Pulmonary Large Cell Neuroendocrine Carcinoma".PATHOLOGY & ONCOLOGY RESEARCH 28(2022).